Orlando, FL-A decade's worth of scientific and technological advances appear to have combined to increase society's sensitivity to prostate cancer. Detection rates among younger men have increased, whereas detection rates among older men are falling, according to a study from the Columbia University College of Physicians and Surgeons, New York.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier
November 28th 2023Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.